Already fixed a glaring error....

What happens if those dosed with Apabetalone show improved MoCA scores?

As noted earlier, the primary end point of the BETonMACE trial is not Alzheimer's or Vascular Dementia.  The primary end point is about measuring the time to first occurrence of a Major Adverse Cardiac Event, or MACE for short. Resverlogix is hoping to prove that Apabetalone in tandem with SoC will show a statistically significant Relative Risk Reduction versus placebo with SoC.

If the sub analysis of patients over the age of 70 demonstrates positive benefits in regards to MoCA scores, then I fully expect there would be further clinical trials designed with a goal of measuring cognition.